medigraphic.com
Academia Mexicana de Neurología, A.C.

2017, Number 2

<< Back Next >>

Rev Mex Neuroci 2017; 18 (2)

Clinical diagnosis of atypical parkinsonian disorders

Sánchez-Jordán A, Medina-Rioja R, Boll-Woehrlen MC

Language: Spanish
References: 46
Page: 88-99
PDF size: 412.77 Kb.


ABSTRACT

Parkinsonism is defined as the presence of bradykinesia and at least one of the following: rest tremor, rigidity, or postural instability. Most of the parkinsonism seen at neurological centers represent Parkinson’s disease (PD). Differential diagnosis can be complicated, particularly in early stages when features of PD may overlap with those seen in other movement disorders. Atypical parkinsonian disorders are a group of clinical syndromes with atypical features beyond the classic PD. Progressive supranuclear palsy (PSP), multiple system atrophy (MSA), dementia with Lewy bodies (DLB) and corticobasal degeneration (CBD) are the most prevalent. They all share parkinsonian features which make early diagnosis a challenge for the neurologist. However, it is important to guide management and predict prognosis.


REFERENCES

  1. Gibb WR, Lees AJ. The significance of the Lewy body in the diagnosis of idiopathic Parkinson’s disease. Neuropathol Appl Neurobiol 1989; 15: 27-44.

  2. Litvan I, Mangone CA, McKee A, Verny M, Parsa A, Jellinger K, et al. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. J Neurol Neurosurg Psychiatr 1996; 60: 615-20.

  3. Schrag A, Ben-Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet 1999; 354: 1771-5.

  4. Nath U, Ben-Shlomo Y, Thomson RG, Morris HR, Wood NW, Lees AJ, et al. The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK. Brain 2001; 124: 1438-49.

  5. Golbe LI, Davis PH, Schoenberg BS, Duvoisin RC. Prevalence and natural history of progressive supranuclear palsy. Neurology 1998; 38: 1031-4.

  6. Litvan I, Agid Y, Jankovic J, Goetz C, Brandel JP, Lai EC, et al. Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy. Neurology 1996; 46: 922-30.

  7. Williams DR, de Silva R, Paviour DC, Pittman A, Watt HC, Kilford L, et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson’s syndrome and PSP-parkinsonism. Brain 2005; 128: 1247-58.

  8. Williams DR, Lees AJ. What features improve the accuracy of the clinical diagnosis of progressive supranuclear palsy-parkinsonism (PSP-P)? Mov Disord 2010; 25: 357-62.

  9. Williams DR, Holton JL, Strand K, Revesz T, Lees AJ. Pure akinesia with gait freezing: a third clinical phenotype of progressive supranuclear palsy. Mov Disord 2007; 22: 2235-41.

  10. Tsuboi Y, Josephs KA, Boeve BF, Litvan I, Casselli RJ, Caviness JN, et al. Increased tau burde in the cortices of progressive supranuclear palsy presenting with corticobasal syndrome. Mov Disord 2005; 20: 982-8.

  11. Josephs KA, Boeve BF, Duffy JR, Smith GE, Knopman DS, Parisi JE, et al. Atypical progressive supranuclear palsy underlying progressive apraxia of speech and nonfluent aphasia. Neurocase 2005; 22: 283-96.

  12. Warren NM, Burn DJ. Progressive supranuclear palsy. Pract Neurol 2007; 7: 16-23.

  13. Dubois B, Slachevsky A, Pillon B, et al. Applause sign helps to discriminate PSP from FTD and PD. Neurology 2006; 64: 2132-3.

  14. Schrag A, Good CD, Miszkiel K, Morris HR, Mathias CJ, Lees AJ, et al. Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology 2000; 54: 697-702.

  15. Boeve BF. Progressive supranuclear palsy. Parkinsonism Relat Disord 2012; 18S1: S192-4.

  16. Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology 1997; 49: 1284-8.

  17. Wenning GK, Geser F, Krismer F, Seppi K, Duerr S, Boesch S, et al. The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol 2013; 12: 264-74.

  18. Wenning GK, Ben-Shlomo Y, Magalhaes M, Daniel SE, Quinn NP. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain 1994; 117: 835-45.

  19. Gilman S, Low PA, Quinn N, Albanese A, Ben-Schlomo Y, Fowler CJ, et al. Consensus statement on the diagnosis of multiple system atrophy. J Auton Nerv Syst 1998; 74: 189-92.

  20. Gilman S, May SJ, Shults CW, Tanner CM, Kukull W, Lee VM, et al. The North American Multiple System Atrophy Study Group. J Neural Transm 2005; 112: 1687-94.

  21. Köllensperger M, Geser F, Ndayisaba JP, Boesch S, Seppi K, Ostergaard K, et al. Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov Disord 2010; 25: 2604-12.

  22. Kim HJ, Jeon BS, Lee JY, Yun JY. Survival of Korean patients with multiple system atrophy. Mov Disord 2011; 26: 909-12.

  23. Watanabe H, Saito Y, Terao S, Ando T, Kachi T, Mukai E, et al. Progression and prognosis in multiple system atrophy: an análisis of 230 Japanese patients. Brain 2002; 125: 1070-83.

  24. Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008; 71: 670-6.

  25. Osaki Y, Ben-ShlomoY, Lees AJ, Wenning GK, Quinn NP. A validation exercise on the new consensus criteria for multiple system atrophy. Mov Disord 2009; 24: 2272-6.

  26. Stankovic I, Krismer F, Jesic A, Antonini A, Benke T, Brown NG, et al. Cognitive impairment in multiple system atrophy: A position statement by the Neuropsychology Task Force of the MDS multiple system atrophy (MODIMSA) Study Group. Mov Disord 2014; 29(7): 857-67.

  27. Munschauer FE, Loh L, Bannister R, Newsom-Davis J. Abnormal respiration and sudden death during sleep in multiple system atrophy with autonomic failure. Neurology 1990; 40: 677-9.

  28. Vetrugno R, D’Angelo R, Cortelli P, Piazzi G, Vignatelli L, Montagna P. Impaired cortical and autonomic arousal during sleep in multiple system atrophy. Clin Neurophysiol 2007; 118: 2512-8.

  29. Rebeizz JJ, Kolodny EH, Richardson EP Jr. Corticodentatonigral degeneration with neural achromasia: a progressive disorder in late adult life. Trans Am Neurol Assoc 1967; 92: 23-6.

  30. Gibb WR, Luthert PJ, Marsden CD. Corticobasal degeneration. Brain 1989; 112:1171-92.

  31. Stamelou M, Alonso-Canovas A, Bhatia KP. Dystonia in corticobasal degeneration: a review of the literature on 404 pathology proven cases. Mov Disord 2012; 27: 696-702.

  32. Stamelou M, Bhatia KP. Atypical parkinsonism diagnosis and treatment. Neurol Clin 2015; 33: 39- 56.

  33. Armstrong MJ, Litvan I, Lang AE, Bak TH, Bahtia KP, Borroni B, et al. Criteria for the diagnosis of corticobasal degeneration; Neurology 2013; 80: 496-503.

  34. Grimes DA, Lang AE, Bergeron CB. Dementia as the most common presentation of cortical-basal ganglionic degeneration. Neurology 1999; 53: 1969-74.

  35. Murray R, Neumann M, Forman MS, Farmer J, Massimo L, Rice A, et al. Cognitive and motor assessment in autopsy-proven corticobasal degeneration. Neurology 2007; 68: 1274-83.

  36. Lee SE, Rabinovici GD, Mayo MC, Wilson SM, Seeley WW, DeArmond SJ, et al. Clinicopathological correlations in corticobasal degeneration. Ann Neurol 2011; 70: 327-40.

  37. Kompoliti K, Goetz CG, Boeve BF, Maraganore DM, Ahlskog JE, Marsden CD, et al. Clinical presentation and pharmacological therapy in corticobasal degeneration. Arch Neurol 1998; 55: 957,61.

  38. Ling H, O’Sullivan SS, Holton JL, Revesz T, Massey LA, Williams DR, et al. Does corticobasal degeneration exist? A clinicopathologic re-evaluation. Brain 2010; 133: 2045-57.

  39. Wenning GK, Litvan I, Jankovic J, Granata R, Mangone CA, McKee A, et al. Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. J Neurol Neurosurg Psychiatry 1998. 64; 184-9.

  40. Zaccai J, McCracken C, Brayne C. A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Age Ageing 2005; 34: 561-6.

  41. Kraybill ML, Larson EB, Tsuang DW, Teri L, McCormick WC, Bowen JD. Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both. Neurology 2005, 64:2069–73.

  42. Weisman D, Cho M, Taylor C, Adame A, Thal LJ, Hansen LA. In dementia with Lewy bodies, Braak stage determines phenotype, not Lewy body distribution. Neurology 2007, 69:356–9.

  43. McKeith I, Cummings J. Behavioral changes and psychological symptoms in dementia disorders. Lancet Neurol 2005; 4(11): 735-42.

  44. Mitolo M, Salmon DP, Gardini S, Galasko D, Grossi E, Caffarra P, et al. The new qualitative scoring MMSE pentagon test (QSPT) as a valid screening tool between autopsy-confirmed dementia with Lewy bodies and Alzheimer’s disease. J Alzheimer Dis 2014; 39(4): 823-32.

  45. Cagnin A, Cinzia B, Jelcic N, Gnoato F, Mitolo M, Caffara P. High specifity of MMSE pentagon scoring for diagnosis of prodromal dementia with Lewy bodies. Parkinsonism Relat Disord 2015; 21: 303-5

  46. McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of DLB consortium. Neurology 2005; 1863-72.




2020     |     www.medigraphic.com